Hem › Neuroblastom › Massachusetts
Kliniska studier för Neuroblastom i Massachusetts
13 studier för Neuroblastom söker deltagare vid platser i Massachusetts.
Städer i Massachusetts
Officiell studietext (engelska)
Dinutuximab With Chemotherapy, Surgery and Stem Cell Transplantation for the Treatment of Children With Newly Diagnosed High Risk Neuroblastoma
- Massachusetts General Hospital Cancer Center, Boston
- Dana-Farber Cancer Institute, Boston
RekryterarFas 3
Upp till ålder 30 · Alla kön · Uppdaterad 2 okt. 2026 · NCT06172296MCT for the Harvard/UCSF ROBIN Center
- Brigham and Women's Hospital, Boston
Rekryterar
Alla åldrar · Alla kön · Uppdaterad 1 okt. 2026 · NCT06000787Substudy 01A: Zilovertamab Vedotin in Pediatric and Young Adult Participants With Hematologic Malignancies or Solid Tumors (MK-9999-01A/LIGHTBEAM-U01)
- Dana-Farber Cancer Institute ( Site 1013), Boston
RekryterarFas 1/2
6 Months – 25 Years · Alla kön · Uppdaterad 17 sep. 2026 · NCT06395103B7-H3.CD28Z.CART in Solid Tumors
- Dana Farber Cancer Institite, Boston
RekryterarFas 1
9 Months – 30 Years · Alla kön · Uppdaterad 3 sep. 2026 · NCT07358260Testing the Addition of 131I-MIBG or Lorlatinib to Intensive Therapy in People With High-Risk Neuroblastoma (NBL)
- Massachusetts General Hospital Cancer Center, Boston
- Dana-Farber Cancer Institute, Boston
RekryterarFas 3
365 Days – 30 Years · Alla kön · Uppdaterad 25 aug. 2026 · NCT03126916Tegavivint for the Treatment of Recurrent or Refractory Solid Tumors, Including Lymphomas and Desmoid Tumors
- Dana-Farber Cancer Institute, Boston
RekryterarFas 1/2
12 Months – 30 Years · Alla kön · Uppdaterad 25 aug. 2026 · NCT04851119SPEARHEAD-3 Pediatric Study
- Dana Farber Cancer Institute, Boston
RekryterarFas 1/2
Ålder 2 till 21 · Alla kön · Uppdaterad 11 aug. 2026 · NCT05642455PEEL-224, Vincristine and Temozolomide in Pediatric Solid Tumors
- Boston Children's Hospital, Boston
- Dana-Farber Cancer Institute, Boston
RekryterarFas 1/2
Ålder 1 till 30 · Alla kön · Uppdaterad 22 juli 2026 · NCT06721689NANT 2021-01 Phase II STING (Sequential Temozolomide, Irinotecan, NK Cells and GD2 mAb) Trial
- Boston Children's Hospital, Dana-Farber Cancer Institute., Boston
RekryterarFas 2
Ålder 1 till 31 · Alla kön · Uppdaterad 20 juli 2026 · NCT06450041Feasibility Study of Prolonged Administration of Naxitamab, Irinotecan, and Temozolomide for Patients With Relapsed or Refractory Neuroblastoma
- Boston Children's Hospital, Boston
- Dana-Farber Cancer Institute, Boston
RekryterarFas 1
Ålder 1 till 30 · Alla kön · Uppdaterad 14 juli 2026 · NCT07027748Neuroblastoma Biology Study
- Children's Hospital Boston, Boston
RekryterarObservationsstudie
31 Days – 99 Years · Alla kön · Uppdaterad 23 mars 2026 · NCT01587300Resource Intervention to Support Equity (RISE) in High-Risk Neuroblastoma
- Dana-Farber Cancer Institute, Boston
Rekryterar
Upp till ålder 17 · Alla kön · Uppdaterad 10 feb. 2026 · NCT06831552Study of hALK.CAR T Cells for Patients With Relapsed/Refractory High-risk Neuroblastoma
- Boston Children's Hospital, Boston
- Dana-Farber Cancer Institute, Boston
RekryterarFas 1/2
12 Months – 29 Years · Alla kön · Uppdaterad 26 dec. 2025 · NCT06803875Från ClinicalTrials.gov, data hämtad 5 okt. 2026. Varje studie har egna kvalifikationskrav; studieteamet avgör vem som kan delta.